Curated by Editor in Chief George Lundberg, MD:
When overall clinical trial results are presented as “medians,” obviously, the same number of patients lived longer as did those who lived less long than the median. It can be useful to study the “tail” of the long survivors for clues of combinations of treatments that may help others. A July 2019 Journal of Neuro-Oncology paper explores this topic.